CION Ameerpet
Your report carries a subtype, a stage and a grade, and the grade is usually the line nobody has time to explain. In plain terms, the ovarian cancer grade describes how abnormal the tumour cells look under a microscope — not how far the disease has spread. In serous ovarian cancer it does something stranger still: it separates two diseases that happen to share a name.
The ovarian cancer grade describes how abnormal the tumour cells look under a microscope. The stage describes how far the disease has travelled through the abdomen. They are separate questions, decided by different evidence: grade comes from the pathologist looking at tissue, stage comes from what the surgeon and the scans found. A tumour can be low-grade and still be widespread, and a high-grade tumour can still be confined to one ovary.
Most people arrive at this page with a mental model borrowed from other cancers, where grade is a dial — a bit abnormal, quite abnormal, very abnormal — and a higher number simply means worse. That model does not transfer. Ovarian cancer is not one disease, it is a family of diseases that share an address, and each member is graded differently. The word “grade” on your report means something quite specific to your subtype, which is why it is worth reading the two lines together rather than fixing on the number.
The clearest example is serous carcinoma, the commonest ovarian cancer. It is graded on just two tiers: low-grade serous and high-grade serous. These are not two speeds of one illness. They arise differently, carry different genetic changes, grow at different rates and respond to treatment in almost opposite ways. Understanding that one fact changes how the rest of your report reads.
How abnormal the nuclei look, and how often the cells are dividing. It is a judgement about biology, made on tissue under a microscope.
Whether disease is confined to the ovaries, has reached the pelvis, has spread across the abdomen, or has travelled further. It is decided by surgery and imaging.
Low-grade serous cancers commonly present at an advanced stage, because they grow quietly for years. A low grade is not a reassurance about stage, or the reverse.
For most of the twentieth century, ovarian serous carcinoma was graded on a three-tier scale borrowed from other cancers — and pathologists frequently disagreed, particularly about what counted as grade 2. In 2004, Malpica and colleagues at MD Anderson proposed a two-tier system: low-grade or high-grade, judged primarily on nuclear atypia, with mitotic rate as a secondary criterion. It proved far more reproducible between pathologists, and it turned out to be describing two genuinely different diseases rather than two speeds of one. The WHO Classification of Female Genital Tumours now uses this two-tier system as standard, and it is the reason a modern report says “high-grade serous” rather than “grade 3 serous”. Source: Malpica A et al., American Journal of Surgical Pathology (2004); WHO Classification of Female Genital Tumours, 5th edition (2020).
Find your subtype in the first column. The grading system used, and how much weight the grade carries, both change depending on which ovarian cancer you have.
| Ovarian cancer type | How the grade is reported | What that grade tells you |
|---|---|---|
| Serous carcinoma | Two tiers only — low-grade serous or high-grade serous. Judged mainly on nuclear atypia, with mitotic rate second. | Not a severity dial. The two behave as separate diseases, with different genetics, different growth rates and near-opposite responses to chemotherapy. |
| Endometrioid carcinoma | A three-tier FIGO grade — 1, 2 or 3 — based on how much of the tumour grows as solid sheets rather than glands, adjusted for nuclear appearance. | Here the grade does work as a gradient. Grade 1 tumours are often confined and hormone-receptor positive; grade 3 behaves much closer to high-grade serous. |
| Clear cell carcinoma | Reported as high grade by convention. No separate grading system is applied, because a grade adds nothing to what the subtype already says. | The subtype carries the information. Response to standard chemotherapy is typically lower than in high-grade serous, which shapes the plan from the start. |
| Mucinous carcinoma | Grading is used inconsistently. Pathologists give more weight to whether invasion is expansile or infiltrative, and to whether the tumour began in the ovary at all. | Pattern of invasion and site of origin matter more than any grade number. A mucinous tumour that spread from the bowel or appendix is treated as that cancer. |
| Immature teratoma | Graded 1 to 3 by how much immature nerve tissue the pathologist finds across the sampled sections. | One of the few places where the grade number directly drives the decision on whether chemotherapy follows surgery at all. |
| Borderline tumours | Not graded. They sit in a separate category — tumours of low malignant potential — because they do not invade in the usual way. | A borderline report is not a low-grade cancer report. It is a different diagnosis, with a different outlook and a different follow-up plan. |
*Subtype and grade are the two lines on a report most likely to change when the slides are reviewed by a second specialist gynaecologic pathologist. If either looks uncertain, ask for that review before treatment is finalised — and read our guide to your ovarian cancer pathology report alongside this page.
None of these is a challenge to your doctor. They are the questions a specialist would ask about their own report, and any oncologist will expect them.
Two-tier serous, or a three-tier grade? The same number carries different meaning depending on which system the pathologist applied.
A needle or laparoscopic biopsy samples a small part of the tumour. The grade can be revised once the whole specimen is examined after surgery.
Low-grade serous and clear cell are uncommon. If the report reads oddly for the subtype, asking for a second pathology opinion is reasonable, not rude.
Ask specifically whether it alters the chemotherapy plan, the maintenance plan or the follow-up interval. If it changes nothing, that is worth knowing too.
In high-grade serous disease this testing shapes maintenance decisions and has implications for your relatives. It is done in-house at CION.
Ask whether your pathology, imaging and history are being discussed by a multidisciplinary tumour board, or interpreted by one doctor alone.
Take the report itself to the appointment rather than a photograph of one page. The grade means little without the subtype, the stage and the surgeon's note on how much disease was removed.
A 45-minute consultation with the report in front of you: what the grade means, whether it changes the treatment plan, and what to ask before anything is started. The first consultation is free.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Bring the pathology report — we will go through it with you line by line.
The grade is not a score to worry over. It is an input into five or six specific decisions, and it is worth knowing exactly which ones it touches.
This is where grade does its most decisive work. In a cancer confined to one ovary that has been completely staged at surgery, a grade 1 endometrioid tumour may reasonably be watched rather than treated further, because the risk of recurrence is low enough that chemotherapy is unlikely to add much. The same stage with a higher grade is a different conversation, and adjuvant chemotherapy is usually advised.
That is also why complete surgical staging matters so much in apparently early disease. Without a proper look at the whole abdomen, nobody can be confident the disease is confined, and the grade alone cannot carry that decision.
Here is the part that surprises most people. High-grade serous carcinoma is the more aggressive disease, but it is usually markedly sensitive to platinum-based chemotherapy, at least initially, because rapidly dividing cells are exactly what that treatment targets. Low-grade serous carcinoma grows slowly and is relatively resistant to conventional chemotherapy, and response rates are modest.
So a high grade is not a straightforwardly worse position to be in at the start of treatment. It means the disease tends to be more advanced when it is found and more likely to recur later, but also that the first line of treatment usually works well. A low grade means the opposite trade: slower disease, but fewer easy levers to pull.
Low-grade serous and grade 1 endometrioid tumours are frequently oestrogen- and progesterone-receptor positive, and hormonal treatment is an accepted option in that setting, sometimes as maintenance after chemotherapy and sometimes in place of it. This is one of the practical reasons the grade is worth reading carefully rather than skimming past.
In high-grade serous disease, hormonal treatment plays a much smaller part. If your report shows a low-grade or grade 1 tumour, ask whether receptor testing has been done, and what the result was. More on the options on our ovarian cancer treatment page.
Germline BRCA testing should be offered to everyone diagnosed with a non-mucinous epithelial ovarian cancer, whatever the family history, because a substantial minority carry a variant that nobody expected. Tumour HRD testing looks at whether the cancer has lost its ability to repair DNA in a particular way, and it is most informative in high-grade serous and high-grade endometrioid disease.
These results feed directly into maintenance decisions after chemotherapy, and into whether your sisters, daughters and brothers should be offered testing themselves. Genetic counselling, BRCA testing and HRD testing are all delivered in-house at CION rather than referred out.
Across every grade and every subtype, one of the strongest influences on outcome is how much visible disease is left behind after surgery. A high grade does not make that less true, and a low grade does not make it optional. This is the decision worth spending your energy on.
At CION, staging surgery, debulking and interval debulking are coordinated with specialist gynaecologic-oncology surgeons at partner centres, and may be billed there. We say that plainly rather than let you discover it later. Chemotherapy, maintenance therapy and follow-up are delivered by CION itself, across 35+ centres in Telangana and Andhra Pradesh.
High-grade disease tends to recur earlier, so the first two to three years of follow-up are the most intensive. Low-grade disease can recur late — sometimes many years after treatment — which is an argument for follow-up that continues rather than quietly stopping at the five-year mark.
Follow-up is built from clinical review, your symptoms, and the trend in CA-125 where it was raised to begin with. A single CA-125 value means very little on its own; the direction of travel over several readings means considerably more. None of this is screening, and it is not a promise that a recurrence will be caught before it causes symptoms.
A pathology report is written by one specialist for another. It is precise, it is compressed, and it is almost never explained at the pace a newly diagnosed person can absorb. Most of the distress we see in the first fortnight after a diagnosis comes from a single word on that report that nobody had ten minutes to unpack. Your first consultation at CION is free and runs to about 45 minutes, which is long enough to read the report together, line by line, and to say what each line does and does not decide.
What CION delivers in-house is medical oncology: platinum-based and other chemotherapy, maintenance therapy, genetic counselling with BRCA and HRD testing, nutrition support and long-term follow-up, across 35+ centres in Telangana and Andhra Pradesh. Staging surgery, debulking and interval debulking are coordinated with specialist gynaecologic-oncology surgeons at partner centres and may be billed there. Every case that raises a question is discussed at a tumour board rather than decided by one doctor alone.
People almost always ask what the grade means for survival. The honest answer is that published grade-specific figures mislead more often than they help: they are historical, they average across substages and subtypes, and they mix women whose surgery cleared all visible disease with women whose surgery did not. What we can show you is our own record against the national one. For ovarian cancer, 81.0% of CION patients are alive at one year, against a national figure of 73.7%. Those are one-year figures across a whole treated population — not cure rates, and not a prediction for you. Read the complete ovarian cancer guide for how stage, subtype and grade fit together.
Free, unhurried, with a specialist and with your report open on the table. Long enough to ask the same question twice if you need to.
Pathology, imaging and history reviewed by a multidisciplinary group — medical oncology, radiology and pathology together — not a single clinician's call.
Genetic counselling before and after testing, so a result changes your plan and your family's screening rather than sitting in a file.
Chemotherapy, maintenance and follow-up delivered close to where you live, rather than requiring repeated trips to one city hospital.
*One-year survival rates. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups, not individuals — discuss your own prognosis with your treating oncologist.
Grade describes how abnormal the tumour cells look under a microscope. Stage describes how far the disease has spread through the abdomen and beyond. They are answered by different evidence: the grade comes from the pathologist examining tissue, the stage comes from what the surgeon found and what the scans show. The two do not track each other. Low-grade serous cancers frequently present at an advanced stage because they grow quietly over years, while a high-grade tumour can occasionally be caught while still confined to one ovary. When you are told a grade, the useful follow-up question is always what the stage is, and how completely the disease was removed at surgery.
It means the pathologist has identified the commonest type of ovarian cancer, in which the cell nuclei are markedly abnormal and the cells are dividing rapidly. High-grade serous carcinoma is now understood to begin, in most cases, at the far end of the fallopian tube rather than in the ovary itself, and it carries an abnormality of the TP53 gene in almost every case. It grows quickly, which is why it is usually found once it has spread. The same rapid division also makes it markedly sensitive to platinum-based chemotherapy at the start of treatment. It is the subtype where BRCA and HRD testing matters most, because those results shape maintenance treatment after chemotherapy.
It is less aggressive, but that does not make it a milder version of the same illness. Low-grade serous carcinoma is a biologically different disease. It grows slowly, which means it is often widespread by the time it is found, and it is relatively resistant to conventional chemotherapy, so the treatment that works well against high-grade disease works less well here. Its advantages lie elsewhere: it is frequently hormone-receptor positive, so hormonal treatment has a genuine role, and it tends to progress over years rather than months. Treat a low-grade diagnosis as a different problem with different tools, not as good news or bad news.
For a serous carcinoma, in practice yes. Older three-tier grading systems described serous tumours as grade 1, 2 or 3, and when those reports are mapped onto the modern two-tier system, both grade 2 and grade 3 sit in the high-grade category, while grade 1 corresponds to low-grade. For endometrioid carcinoma, though, grade 3 means something specific in its own right: it is a genuine three-tier FIGO grade based on how much of the tumour grows as solid sheets. This is exactly why it is worth asking which grading system your report used. It also explains why a grade 3 ovarian cancer and a grade 3 breast cancer are not comparable, since the two are graded on entirely different criteria.
On average, high-grade disease behaves more aggressively, and the published survival figures reflect that. But those figures mislead more often than they help an individual. They are historical, they average across substages and subtypes, and they combine women whose surgery cleared all visible disease with women whose surgery did not, which is one of the strongest influences on outcome. Grade is one input among several. Stage, how completely surgery removed disease, whether the tumour carries a BRCA or HRD change, and your general health all carry weight. A number drawn from a group of thousands of women, treated years ago, is not a forecast for you. Ask your oncologist about your own situation instead.
Yes, and it is not unusual. A grade taken from a needle or laparoscopic biopsy is based on a small sample, and the whole specimen removed at surgery sometimes shows a different picture. Subtype and grade are also the two findings most likely to be revised when slides are reviewed by a second specialist gynaecologic pathologist, particularly for the less common subtypes. That is a normal part of careful practice rather than a sign anything went wrong. If your treatment plan turns on the grade, ask whether a review has been done, and ask for one before treatment is finalised if it has not.
The first consultation is free and runs to about 45 minutes, which is long enough to go through your pathology report properly. CION delivers medical oncology for ovarian cancer in-house: chemotherapy and maintenance treatment across more than 35 centres in Telangana and Andhra Pradesh, along with genetic counselling, BRCA and HRD testing, nutrition support and long-term follow-up. Staging surgery, debulking and interval debulking are coordinated with specialist gynaecologic-oncology surgeons at partner centres and may be billed there, and we say so upfront rather than leaving it to be discovered later. Every case that raises a question is reviewed at a tumour board.